research 1112 An innovative phase 1b trial demonstrating proof-of-pharmacology for two novel IRAK4-inhibitors using a local (Imiquimod) and systemic (LPS) driven immune response
This study found that the oral IRAK4-inhibitors BAY 1834845 and BAY 1830839 reduced skin inflammation and systemic inflammatory responses in healthy volunteers, showing similar pharmacodynamic effects to prednisolone when challenged with topical imiquimod and intravenous LPS.